USRE46364E1 - Fibrosis inhibitor - Google Patents

Fibrosis inhibitor Download PDF

Info

Publication number
USRE46364E1
USRE46364E1 US15/155,202 US200915155202A USRE46364E US RE46364 E1 USRE46364 E1 US RE46364E1 US 200915155202 A US200915155202 A US 200915155202A US RE46364 E USRE46364 E US RE46364E
Authority
US
United States
Prior art keywords
added
control group
present
manufactured
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/155,202
Other languages
English (en)
Inventor
Koji Murakami
Takuya Toramoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to US15/155,202 priority Critical patent/USRE46364E1/en
Assigned to NIPPON SHINYAKU CO., LTD. reassignment NIPPON SHINYAKU CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MURAKAMI, KOJI, TORAMOTO, TAKUYA
Application granted granted Critical
Publication of USRE46364E1 publication Critical patent/USRE46364E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a fibrosis inhibitor containing a heterocyclic derivative (hereinafter, referred to as “the present heterocyclic derivative (1)”) represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient;
  • R 1 and R 2 are the same or different and each represents an optionally substituted aryl, wherein the substitutions are the same or different and one to three substitutions are selected from the group consisting of halogen atom, alkyl, haloalkyl, arylalkyl, alkoxy, alkylthio, alkoxyalkyl, alkylsulfonyl, hydroxy, amino, monoalkylamino, dialkylamino, carboxy, cyano and nitro;
  • R 3 and R 4 are the same or different and each represents hydrogen atom or alkyl
  • R 5 represents hydrogen atom, alkyl or halogen atom
  • Y represents N or N ⁇ O
  • A represents NR 6 , and R 6 represents hydrogen atom, alkyl, alkenyl or cycloalkyl;
  • D represents alkylene or alkenylene which is optionally substituted with hydroxy, or A and D are combined with each other to torn a divalent group represented by the following formula (2)
  • r represents an integer of 0 to 2
  • q represents 2 or 3
  • t represents an integer of 0 to 4;
  • E represents phenylene or a single bond, or D and E are combined with each other to form a divalent group represented by the following formula (3)
  • u represents an integer of 0 to 2 and v represents 0 or 1;
  • G represents O, S, SO or SO 2 ;
  • Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl or the group represented by the following formula (4).
  • R 7 represents amino, monoalkylamino, dialkylamino, hydroxy, any of the group of the following 1) to 4) which are optionally substituted with 1 to 3 substituents selected from the group consisting of halogen atom, alkyl, haloalkyl, arylalkyl, alkoxy, alkylthio, alkoxyalkyl, alkylsulfonyl, hydroxy, amino, monoalkylamino, dialkylamino, carboxy, cyano and nitro;
  • Fibrosis of organs occurs in such a manner that extracellular matrix is excessively accumulated in the organs through invasion or injury of organs due to some cause.
  • cicatrix does not remain and the organs return to normal.
  • fibrosis of the cicatrix gives impairment of its inherent function. Further, it induces new fibrosis and generates a vicious cycle of fibrosis, finally, dysfunction of organs occurs.
  • Interstitial pneumonia is a disease where inflammation happens in alveolar wall due to some causes; fibroblasts proliferate in interstitial tissues; the lung is sclerosed by an excessive sedimentation of collagen fibers; gas exchange is disturbed; and, finally, respiratory failure occurs. After onset of the disease, the patient dies within three to five years in average. The detailed mechanism of pathogenesis of interstitial pneumonia has not been clarified yet and no established treating method has been available yet as well.
  • the present heterocyclic derivative (1) or a pharmaceutically acceptable salt thereof has already been reported to be useful for the treatment of pulmonary hypertension and obstructive arteriosclerosis as a PGI 2 receptor agonist (see, for example, Patent Document 1).
  • the main object of the present invention is to provide a novel fibrosis inhibitor.
  • the present inventors have found that the present heterocyclic derivative (1) has an inhibitory effect of the growth of fibroblasts and have achieved the present invention.
  • An example of the present invention is a fibrosis inhibitor containing the present heterocyclic derivative (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • R 1 and R 2 are the same or different and each represents optionally substituted phenyl, and the substitutions are the same or different and one to three substitutions are selected from the group consisting of halogen atom, alkyl and alkoxy;
  • R 3 and R 4 are the same or different and each represents hydrogen atom or alkyl
  • R 5 represents hydrogen atom
  • Y represents N
  • A represents NR 6 , and R 6 represents alkyl
  • D represents alkylene
  • G represents O
  • Q represents carboxy or a group represented by the following formula (4)
  • R 7 represents amino, monoalkylamino, dialkylamino, hydroxy, or any of the group of the following 1) to 4) which are optionally substituted with 1 to 3 substituents selected from the group consisting of halogen atom, alkyl, haloalkyl, arylalkyl, alkoxy, alkylthio, alkoxyalkyl, alkylsulfonyl, hydroxy, amino, monoalkylamino, dialkylamino, carboxy, cyano and nitro;
  • the compound A 2- ⁇ 4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy ⁇ acetic acid (hereinafter, referred to as “the compound A”) and 2- ⁇ 4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyl-oxy ⁇ -N-(methylsulfonyl)acetamide (hereinafter, referred as “the compound B”) are preferable for example.
  • alkyl in the present invention, that which is straight or branched having 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl or isohexyl may be exemplified. Particularly, alkyl having 1 to 4 carbon atoms is preferable.
  • alkyl moiety in “haloalkyl”, “arylalkyl”, “alkylthio”, “alkoxyalkyl”, “alkylsulfonyl”, “monoalkylamino”, “dialkylamino”, “monoalkylcarbazoyl” and “dialkylcarbamoyl” in the present invention that which is the same as the already-mentioned alkyl may be exemplified.
  • alkoxy in the present invention, that which is straight or branched having 1 to 6 carbon atoms, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, n-hexyloxy or isohexyloxy may be exemplified. Particularly, alkoxy having 1 to 4 carbon atoms is preferable.
  • alkoxycarbonyl and “alkoxyalkyl” in the present invention, that which is the same as the already-mentioned alkoxy may be exemplified.
  • alkenyl in the present invention, that which is straight or branched having 2 to 6 carbon atoms, for example, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-henexyl or 5-hexenyl may be exemplified. Particularly, alkenyl having 3 or 4 carbon atoms is preferable.
  • cycloalkyl in the present invention, that which has 3 to 8 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl cr cyclooctyl may be exemplified. Particularly, cycloalkyo having 5 to 7 carbon atoms is preferable.
  • halogen atom in the present invention, fluorine atom, chlorine atom, bromine atom and iodine atom may be exemplified.
  • aryl in the present invention, that which has 6 to 10 carbon atoms, for example, phenyl, 1-naphthyl or 2-naphthyl may be exemplified. Particularly, phenyl is preferable.
  • arylalkyl and “aryloxy” in the present invention, that which is the same as in the already-mentioned aryl may be exemplified.
  • alkylene in the present invention, that which is straight or branched having 1 to 8 carbon atoms, for example, methylene, ethylene, 1-methylethylene, 2-methylethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene or octamethylene may be exemplified. Particularly, alkylene having 3 to 6 carbon atoms is preferable, and alkylene having 4 carbon atoms is more preferable.
  • alkenylene that which is straight or branched having 2 to 8 carbon atoms
  • ethenylene 1-propenylene, 2-propenylene, 1-butenylene, 2-butenylene, 3-butenylene
  • 4-pentenylene, 4-methyl-3-pentenylene, 1-hexenylene, 2-hexenylene, 3-hexenylene, 4-hexenylene, 5-hexenylene, 1-heptenylene, 2-heptenylene, 3-heptenylene, 4-heptenylene, 5-heptenylene, 6-heptenylene, 1-octenylene, 2-octenylene, 3-octenylene, 4-octenylene, 5-octenylene, 6-octenylene or 7-octenylene may be exemplified.
  • alkenylene having 3 to 6 carbon atoms is prefer
  • heterocyclic group in the present invention, the following (1) or (2) may be exemplified.
  • a five- to six-membered aromatic ring group having 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, or a benzene condensed ring thereof and nitrogen atom and sulfur atom may form an oxide when a ring-constituent atom is nitrogen atom or sulfur atom.
  • Examples thereof include 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-indolyl, 2-furanyl, 3-furanyl, 3-benzofuranyl, 2-thienyl, 3-thienyl, 3-benzothienyl, 1,3-oxazol-2-yl, 4-isoxazolyl, 2-thiazolyl, 5-thiazolyl, 2-benzothiazolyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 2-benzimidaolyl, 1H-1,2,4-triazol-1-yl, 1H-tetrazol-5-yl, 2H-tetrazol-5-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyrazolyl, 2-pyrimidinyl 4-pyrimidinyl, 2-pyrazinyl, and 1,3,5-triazin-2-yl.
  • a four- to eight-membered saturated ring group which optionally has one to four same or different nitrogen atom, oxygen atom or sulfur atom, or a benzene condensed ring thereof, and nitrogen atom and sulfur atom may form an oxide when a ring-constituent atom is nitrogen atom or sulfur atom.
  • nitrogen atom and sulfur atom may form an oxide when a ring-constituent atom is nitrogen atom or sulfur atom.
  • Examples thereof include piperidino, piperazinyl, 3-methylpiperazin-1-yl, homopiperazinyl, morpholino, thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl and 2-tetrahydrofuranyl.
  • the present heterocyclic derivative (1) is able to be synthesized by the process mentioned in the above-mentioned Patent Document 1 (pamphlet of International Publication WO 02/088084).
  • the present heterocyclic derivative (1) may be used as a pharmaceutical just in a form of free base or acid, it is also possible to use by making into a form of a pharmaceutically acceptable salt by a known method.
  • Examples of the “salt” when the present heterocyclic derivative (1) shows basicity include a salt with inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid or hydrobromic acid and with organic acid such as acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid or camphorsulfonic acid.
  • inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid or hydrobromic acid
  • organic acid such as acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid, ethanesulf
  • Examples of the “salt” when the present heterocyclic derivative (1) shows acidity include alkali metal salt such as sodium salt or potassium salt and alkali earth metal salt such as calcium salt.
  • geometrical isomers Z and E substances
  • each of the geometrical isomers and a mixture thereof are also included in the present heterocyclic derivative (1).
  • Some of the present heterocyclic derivative (1) has asymmetric carbon(s) and each of optical isomers and racemic substance thereof are also included in the present heterocyclic derivative (1).
  • An optical isomer is able to be produced by subjecting the racemic substance prepared as above to an optical resolution by a known method using an optically active acid (such as tartaric acid, benzoyltartaric acid, mandelic acid or 10-camphorsulfonic acid) utilizing the basicity or by using a previously-prepared optically active compound as a material.
  • an optically active acid such as tartaric acid, benzoyltartaric acid, mandelic acid or 10-camphorsulfonic acid
  • the fibrosis inhibitor of the present invention is able to be used for the treatment of the following diseases, for example, in which fibrosis of organs or tissues is involved.
  • the fibrosis inhibitor of the present invention is the present heterocyclic derivative (1) as it is or contains it in a pharmaceutically acceptable, nontoxic and inert carrier at a rate ranging from 0.01 to 99.5% or, preferably, ranging from 0.5 to 90%.
  • the carrier examples include solid, semi-solid or liquid diluent, filler and other auxiliary agents for pharmaceutical formulation. These can be used alone or as a mixture of two or more thereof.
  • the fibrosis inhibitor of the present invention may be in any of the forms of oral preparations such as powder, capsules, tablets, sugar-coated tablets, granules, diluted powder, suspension, liquid, syrup, elixir or troche and parenteral preparations such as injection or suppository in a solid or liquid dose unit. It may also be in a form of a sustained release preparation. Among them, oral preparations such as tablets are particularly preferable.
  • Powder is able to be manufactured by making the present heterocyclic derivative (1) into an appropriate fine size.
  • Diluted powder is able to be manufactured by such a manner that the present heterocyclic derivative (1) is made into an appropriate fine size and then mixed with a pharmaceutical carrier which is similarly made into the fine size such as edible carbohydrate (e.g., starch and mannitol).
  • a pharmaceutical carrier which is similarly made into the fine size such as edible carbohydrate (e.g., starch and mannitol).
  • Flavoring agent, preservative, dispersing agent, coloring agent, perfume, etc. may be optionally added thereto.
  • Capsules are able to be manufactured by such a manner that the powder or diluted powder which is made powdery as mentioned above or granules which will be mentioned under the item for tablets is/are filled in an capsule shell such as gelatin capsule. It is also possible to manufacture in such a manner that the powdery thing is mixed with a lubricant or a fluidizing agent such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol followed by subjecting to a filling operation.
  • a lubricant or a fluidizing agent such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol
  • a disintegrating agent or solubilizing agent such as carboxymethyl cellulose, carboxymethyl cellulose calcium, lowly-substituted hydroxypropyl cellulose, croscarmellose sodium, carboxymethyl starch sodium, calcium carbonate or sodium carbonate is added, efficacy of the pharmaceutical when the capsules are ingested is able to be improved. It is also possible that fine powder of the present heterocyclic derivative (1) is suspended/dispersed in vegetable oil, polyethylene glycol, glycerol or surfactant and wrapped with a gelatin sheet to give a soft capsule preparation.
  • Tablets are able to be manufactured in such a manner that a powdery mixture is prepared by addition of a filler and made into granules or slugs and then a disintegrating agent or a lubricant is added thereto followed by making into tablets.
  • the powdery mixture is able to be manufactured by mixing an appropriately powdered substance with the above diluent or base. If necessary, it is possible to add a binder (such as carboxymethyl cellulose sodium, methyl cellulose, hydroxypropyl methyl cellulose, gelatin, polyvinylpyrrolidone or polyvinyl alcohol), a dissolution retarding agent (such as paraffin), a reabsorbing agent (such as a quaternary salt), an adsorbent (such as bentonite or kaolin), etc. thereto.
  • a binder such as carboxymethyl cellulose sodium, methyl cellulose, hydroxypropyl methyl cellulose, gelatin, polyvinylpyrrolidone or polyvinyl alcohol
  • a dissolution retarding agent such as paraffin
  • a reabsorbing agent such as a quaternary salt
  • an adsorbent such as bentonite or kaolin
  • the powdery mixture is able to be made into granules in such a manner that it is firstly made wet using, for example, syrup, starch paste, acacia, cellulose solution or polymer solution, mixed with stirring and dried followed by grinding.
  • a lubricant such as stearic acid, stearate, talc or mineral oil is added to the granules prepared as such, sticking of the granules each other is able to be prevented.
  • Tablets are also able to be manufactured in such a manner that the present heterocyclic derivative (1) is mixed with a fluid inert carrier and then directly making into tablets without conducting the above steps of making into granules or slugs.
  • the tablets prepared as such are able to be subjected to film coating or sugar coating. It is also possible to apply a transparent or semi-transparent protective coat comprising a tightly closed shellac film, a coat comprising sugar or polymer material or a polished coat comprising wax.
  • the syrup is able to be manufactured by dissolving the present heterocyclic derivative (1) into an appropriate aqueous solution of flavor.
  • the elixir is able to be manufactured using a non-toxic alcoholic carrier.
  • the suspension is able to be manufactured by dispersing the present heterocyclic derivative (1) into a non-toxic carrier. If necessary, it is possible to add a solubilizing agent or an emulsifier (such as ethoxylated isostearyl alcohol or polyoxyethylene sorbitol ester), a preservative or a flavor-endowing agent (such as peppermint oil or saccharine) thereto.
  • a solubilizing agent or an emulsifier such as ethoxylated isostearyl alcohol or polyoxyethylene sorbitol ester
  • a preservative or a flavor-endowing agent such as peppermint oil or saccharine
  • the dose unit formulation for oral administration may be made into microcapsules.
  • the above formulation is also able to be coated or embedded into polymer or wax to obtain a prolonged action or sustained release of the active ingredient.
  • the parenteral preparation is able to be in a liquid dose unit form for subcutaneous, intramuscular or intravenous injection such as in a form of solution or suspension.
  • the parenteral preparation is able to be manufactured in such a manner that a predetermined amount of the present heterocyclic derivative (1) is suspended or dissolved into a non-toxic liquid carrier meeting the purpose of injection such as aqueous or oily medium and then the suspension or solution is sterilized.
  • Non-toxic salt or a solution thereof may be added thereto for making the injection solution isotonic. It is also possible to add a stabilizer, a preservative, an emulsifier and the like.
  • the suppository is able to be manufactured by dissolving or suspending the present heterocyclic derivative (1) into a low-melting and water-soluble or insoluble solid such as polyethylene glycol, cacao fat, semi-synthetic fat/oil (such as Witepsol (registered trade mark)), higher ester (such as myristyl palmitate) or a mixture thereof.
  • a low-melting and water-soluble or insoluble solid such as polyethylene glycol, cacao fat, semi-synthetic fat/oil (such as Witepsol (registered trade mark)), higher ester (such as myristyl palmitate) or a mixture thereof.
  • the dose of the fibrosis inhibitor of the present invention may vary depending upon the state of a patient such as body weight or age, administering route or degree of symptom, a range of 0.01 mg to 1000 mg/day as an amount of the present heterocyclic derivative (1) is generally suitable for an adult and a range of 0.1 mg to 100 mg is more preferable. In some cases, the dose less than the above may be sufficient or, on the other hand, the dose more than the above may be necessary. It is also possible to administer one to several times a day or to administer with an interval of one to several days.
  • Human Lung fibroblasts (manufactured by Lonza Walkersville; hereinafter, the same product will be used) were cultured in growth medium, which consisted of basal medium for human lung fibroblasts (manufactured by Lonza Walkersville; hereinafter, the same product will be used and referred to as “basal medium”) with FGM-2 additional factor set (manufactured by Lonza Walkersville; hereinafter, the same product will be used) under the condition of 37° C. and 5% CO 2 .
  • the human lung fibroblasts were seeded in 96-well plate at 1 ⁇ 10 3 cell/well and incubated overnight in growth medium.
  • the fibroblasts were washed once with 100 ⁇ L of phosphate-buffered saline (manufactured by Nissui Seiyaku; hereinafter, the same product will be used) and 100 ⁇ L of basal medium was added thereto followed by incubation for 24 hours. They were further washed with 100 ⁇ L of phosphate-buffered saline once and then basal medium was added in an amount of 80 ⁇ L/well. Ten ⁇ L of a 100 ⁇ M solution of the compound A or the compound B was added to each well and incubated for 2 hours.
  • the solution added thereto was prepared in such a manner that the compound A or B was previously dissolved in dimethyl sulfoxide (DMSO) and the resulting 10 mM solution was diluted 100-fold with basal medium.
  • DMSO dimethyl sulfoxide
  • DMSO which was diluted 100-fold with basal medium was used.
  • EGF epidermal growth factor
  • cell proliferation activity of the human lung fibroblasts significantly increased by stimulation with EGF.
  • the cell proliferation activity significantly decreased as compared with the control group.
  • Human lung fibroblasts were incubated in growth medium under the condition of 37° C. and 5% CO 2 .
  • the human lung fibroblasts were seeded in 96-well plate at 3 ⁇ 10 3 cell/well and incubated overnight in growth medium.
  • the fibroblasts were washed once with 100 ⁇ L of phosphate-buffered saline. Then basal medium was added thereto and incubation was conducted for 24 hours. They were further washed with 100 ⁇ L of phosphate-buffered saline once and then basal medium was added in an amount of 80 ⁇ L/well. Ten ⁇ L of a 1 ⁇ M solution of the compound A was added to each well and incubated for 2 hours. The solution used therefor was prepared in such a manner that the compound A was previously dissolved in DMSO and the resulting 1 mM solution was diluted 100-fold with basal medium. For the non-stimulated control group and the control group, DMSO which was diluted 100-fold with the basal medium was used.
  • TGF- ⁇ transforming growth factor- ⁇
  • cell proliferation activity of the human lung fibroblasts significantly increased by stimulation with TOF- ⁇ .
  • the cell proliferation activity significantly decreased as compared with that of the control group.
  • Human lung fibroblasts were seeded in 96-well plate at 5 ⁇ 10 3 cells/well and incubated in the growth medium in the same way as in Test Example 1 overnight.
  • the fibroblasts were washed once with 100 ⁇ L of basal medium and 100 ⁇ L of basal medium was added thereto followed by incubating for 24 hours. They were further washed once with 100 ⁇ L of basal medium and then 80 ⁇ L/well of basal medium was added.
  • a 0.1, 1, 10 or 100 ⁇ l solution of the compound A was added in an amount of 10 ⁇ L to each well.
  • the solution used therefor was prepared in such a manner that the compound A was previously dissolved in DMSO and adjusted to a concentration of 10 ⁇ M, 100 ⁇ M, 1 mM or 10 mM, followed by a 100-fold dilution with the basal medium.
  • DMSO which was diluted 100-fold with basal medium was added in an amount of 10 ⁇ L.
  • 10 ⁇ L of 100 ng/mL transforming growth factor ⁇ 1 (TGF ⁇ 1) (manufactured by Pepro Tech; hereinafter, the same product will be used) was added and, for the non-stimulated control group, 10 ⁇ L of basal medium was added.
  • the medium was recovered for measuring the concentration of the type I pro-collagen C terminal peptide (PIP) in the medium, and after an addition of 100 ⁇ L of the basal medium, the cell proliferation activity was measured using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (manufactured by Nacalai Tesque).
  • PIP type I pro-collagen C terminal peptide
  • Measurement of the cell proliferation activity was conducted in such a manner that 10 ⁇ L of a 5 mg/mL MTT stock solution was added to each well, and after incubation fur 4 hours, 100 ⁇ L of a 0.04M isopropanol solution of hydrochloric acid was added to each well, followed by the absorbance measurement at 595 nm (reference wavelength: 655 nm) using a microplate reader.
  • the PIP concentration after incubation for 48 hours was measured using a type I pro-collagen C-peptide (PIP) EIA kit (manufactured by Takara; hereinafter, the same one will be used) in accordance with the manual attached thereto.
  • the evaluation of this test was carried out using the value (index for collagen production) calculated as a relative value where a mean value of the non-stimulated control group was defined as 1 after correcting the measured value of PIP concentration for the cell proliferation activity value (absorbance).
  • Human lung fibroblasts were seeded in 24-well plate at 1 ⁇ 10 5 cells/well and incubated in growth medium in the same way as in Test Example 1 overnight.
  • the fibroblasts were washed once with 500 ⁇ L of basal medium, and added with 500 ⁇ L of basal medium followed by incubation for 24 hours. They were further washed once with 500 ⁇ L of basal medium and then 400 ⁇ L/well of basal medium was added.
  • a 1, 10 or 100 ⁇ M solution of the compound A prepared by the same manner as in Test Example 3 was added in an amount of 50 ⁇ L to each well.
  • DMSO which was diluted 100-fold with basal medium was added in an amount of 50 ⁇ L.
  • expressed amount of mRNA for type I collagen ⁇ 1 chain (COL 1 ⁇ 1), type I collagen ⁇ 2 chain (COL 1 ⁇ 2), ⁇ smooth muscle actin (ACTA), TGF ⁇ 1 and glyceraldehydes 3-phosphate dehydrogenase (GAPDH) were measured by means of a real-time quantitative PCR method.
  • the real-time quantitative PCR was conducted using Platinum SYBR Green qPCR Super-Mix-UDG with ROX (manufactured by Invitrogen) and a primer being specific to each gene in accordance with the manual attached to the Platinum SYBR Green qPCR Super-Mix-UDG with ROX using ABI PRISM 7000 (Applied Biosystems).
  • mRNA expression level calculated as a relative value where a mean value of the non-stimulated control group was defined as 1 after correcting the expressed value of mRNA of each gene for the expressed amount of mRMA of GAPDH.
  • each mRNA expression level increased by stimulation with TGF ⁇ l.
  • each mRNA level decreased as compared with that of the control group.
  • Rat renal interstitial cells (NRF 49F cells) were seeded in 96-well plate at 1 ⁇ 10 4 cells/well and incubated in an Minimum Essential Medium (MEM medium; manufactured by Nippon Seiyaku; hereinafter, the same product will be used) containing 10% of bovine fetal serum (manufactured by JRH Bioscience; hereinafter, the same product will be used) under the condition of 37° C. and 5% CO 2 overnight.
  • MEM medium Minimum Essential Medium
  • bovine fetal serum manufactured by JRH Bioscience; hereinafter, the same product will be used
  • serum-free MEM medium After washing with serum-free MEM medium once, serum-free MEM medium was added in an amount of 80 ⁇ L/well. A 100 ⁇ M solution of the compound A prepared by the same method as in Test Example 1 was added in an amount of 10 ⁇ L to each well.
  • DMSO which was diluted 100-fold with serum-free MEM medium was added in an amount of 10 ⁇ L.
  • 10 ⁇ L of a 100 ng/mL platelet-derived growth factor BB (PDGF BB; manufactured by Sigma) solution was added to each well and, for the non-stimulated control group, 10 ⁇ L of serum-free MEM medium was added followed by incubating.
  • PDGF BB platelet-derived growth factor BB
  • cell proliferation activity was measured by an MTT method in the same way as in Test Example 3.
  • the evaluation of this test was carried out using the value (cell proliferation level) expressed as a relative value where a mean value of absorption of the non-stimulating control group was defined as 1.
  • Human skin fibroblasts (manufactured by Kurabo; hereinafter, the same product will be used) were seeded in 96-well plate at 5 ⁇ 10 3 cells/well and incubated in a Dulbecco's modified Eagle's medium (DMEM medium; manufactured by Nippon Seiyaku; hereinafter, the same product will be used) containing 10% of bovine fetal serum under the condition of 37° C. and 5% CO 2 overnight.
  • the human skin fibroblasts were washed once with an DMEM medium containing no bovine fetal serum (hereinafter, referred to as “serum-free DMEM medium”), and 100 ⁇ L of serum-free DMEM medium was added thereto followed by incubation for 24 hours.
  • serum-free DMEM medium was added in an amount of 80 ⁇ L/well.
  • Ten ⁇ L of the 0.1, 1, 10 or 100 ⁇ M solution of the compound A prepared by the same method as in Test Example 3 was added to each well.
  • DMSO which was diluted 100-fold with serum-free DMEM medium was added in an amount of 10 ⁇ L each and followed by incubating. After incubating for 2 hours, 10 ⁇ L of a 100 ng/mL TGF ⁇ 1 solution was added to each well and, for the non-stimulated control group, each 10 ⁇ L of serum-free MEM medium was added.
  • FIG. 1 shows the inhibitive effects of the compound A and the compound B on the proliferation of human lung fibroblasts stimulated by EGF.
  • An ordinate shows absorbance.
  • FIG. 2 shows the inhibitive effects of the compound A and the compound B on the proliferation of human lung fibroblasts stimulated by TGF ⁇ .
  • An ordinate shows absorbance.
  • FIG. 3 shows the inhibitive effect of the compound A on the production of collagen in human lung fibroblasts stimulated by TGF ⁇ 1.
  • An ordinate shows the value calculated as a relative value where a mean value in the non-stimulated control group was defined as 1 after correcting the measured value for PIP concentration by the cell proliferation activity value (absorbance).
  • FIG. 4 shows the inhibitive effect of the compound A on COL 1 ⁇ 1 mRNA expression in human lung fibroblasts stimulated by TGF ⁇ 1.
  • An ordinate shows a relative value where a mean value in the non-stimulated control group was defined as 1 after correcting the expressed amount of mRNA by COL 1 ⁇ 1 using the expressed amount of mRNA by GAPDH.
  • FIG. 5 shows the inhibitive effect of the compound A on COL 1 ⁇ 2 mRNA expression in human lung fibroblasts stimulated by TGF ⁇ 1.
  • An ordinate shows a relative value where a mean value in the non-stimulated control group was defined as 1 after correcting the expressed amount of mRNA by COL 1 ⁇ 2 using the expressed amount of mRNA by GAPDH.
  • FIG. 6 shows the inhibitive effect of the compound A on ACTA mRNA expression in human lung fibroblasts stimulated by TGF ⁇ 1.
  • An ordinate shows a relative value where a mean value in the non-stimulated control group was defined as 1 after correcting the expressed amount of mRNA by ACTA using the expressed amount of mRNA by GAPDH.
  • FIG. 7 shows the inhibitive effect of the compound A on TGF ⁇ 1 mRNA expression in human lung fibroblasts stimulated by TGF ⁇ 1.
  • An ordinate shows a relative value where a mean value in the non-stimulated control group was defined as 1 after correcting the expressed amount of mRNA by TGF ⁇ 1 using the expressed amount of mRNA by GAPDH.
  • FIG. 8 shows the inhibitive effect of the compound A on the proliferation of rat renal interstitial cells stimulated by PDGF BB.
  • An ordinate shows a relative value where a mean value of absorbance in the non-stimulated control group was defined as 1.
  • FIG. 9 shows the inhibitive effect of the compound A on the production of collagen in human skin fibroblasts stimulated by TGF ⁇ 1.
  • An ordinate shows a value calculated as a relative value where a mean value in the non-stimulated control group was defined as 1 after correcting the measured value of PIP concentration by the cell proliferation activity value (absorbance).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US15/155,202 2008-02-28 2009-02-26 Fibrosis inhibitor Active 2030-02-13 USRE46364E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/155,202 USRE46364E1 (en) 2008-02-28 2009-02-26 Fibrosis inhibitor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008-046999 2008-02-28
JP2008046999 2008-02-28
US12/919,885 US8729086B2 (en) 2008-02-28 2009-02-26 Fibrosis inhibitor
PCT/JP2009/053582 WO2009107736A1 (ja) 2008-02-28 2009-02-26 線維化抑制剤
US15/155,202 USRE46364E1 (en) 2008-02-28 2009-02-26 Fibrosis inhibitor

Publications (1)

Publication Number Publication Date
USRE46364E1 true USRE46364E1 (en) 2017-04-11

Family

ID=41016123

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/155,202 Active 2030-02-13 USRE46364E1 (en) 2008-02-28 2009-02-26 Fibrosis inhibitor
US12/919,885 Ceased US8729086B2 (en) 2008-02-28 2009-02-26 Fibrosis inhibitor
US14/249,884 Active US8889693B2 (en) 2008-02-28 2014-04-10 Fibrosis inhibitor

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/919,885 Ceased US8729086B2 (en) 2008-02-28 2009-02-26 Fibrosis inhibitor
US14/249,884 Active US8889693B2 (en) 2008-02-28 2014-04-10 Fibrosis inhibitor

Country Status (20)

Country Link
US (3) USRE46364E1 (ja)
EP (1) EP2246336B1 (ja)
JP (1) JP5522030B2 (ja)
KR (1) KR101581059B1 (ja)
CN (2) CN101959868A (ja)
AU (1) AU2009218115B2 (ja)
BR (1) BRPI0908491A2 (ja)
CA (1) CA2716554C (ja)
CY (1) CY1123308T1 (ja)
DK (1) DK2246336T3 (ja)
ES (1) ES2817557T3 (ja)
HR (1) HRP20201352T1 (ja)
HU (1) HUE050786T2 (ja)
LT (1) LT2246336T (ja)
MX (1) MX2010008745A (ja)
PL (1) PL2246336T3 (ja)
PT (1) PT2246336T (ja)
RU (1) RU2497525C2 (ja)
SI (1) SI2246336T1 (ja)
WO (1) WO2009107736A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2246336T3 (da) * 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
EP2289518B1 (en) * 2008-06-23 2016-11-02 Nippon Shinyaku Co., Ltd. Therapeutic agent for inflammatory bowel disease
CN105168218A (zh) * 2008-06-23 2015-12-23 日本新药株式会社 椎管狭窄症治疗剂
CA2730599C (en) 2008-07-23 2016-09-13 Toray Industries, Inc. Therapeutic agent for chronic renal failure
US8791122B2 (en) 2009-06-26 2014-07-29 Nippon Shinyaku Co., Ltd. Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
WO2011024874A1 (ja) * 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
NZ742784A (en) 2015-12-02 2024-08-30 Nippon Shinyaku Co Ltd Pharmaceutical composition containing 2-{ 4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy} -n- (methylsulfonyl)acetamide
WO2018019296A1 (zh) * 2016-07-29 2018-02-01 成都苑东生物制药股份有限公司 氨基吡嗪类化合物或盐、异构体、其制备方法及用途
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
TWI801421B (zh) 2017-09-28 2023-05-11 日商日本新藥股份有限公司 結晶
US10407396B2 (en) * 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
KR20200088382A (ko) 2017-11-16 2020-07-22 니뽄 신야쿠 가부시키가이샤 방출 제어 제제
EP3830139A4 (en) 2018-07-27 2022-04-27 Arc Medical Devices, Inc. HIGHLY PURIFIED FUCAN FOR THE TREATMENT OF FIBROUS ADHESIONS
CN108863955B (zh) * 2018-08-03 2021-08-13 成都苑东生物制药股份有限公司 二苯基吡嗪类化合物或其药学上可接受的盐、异构体及其制备方法和用途
US20220313733A1 (en) * 2019-06-11 2022-10-06 Kyoto University Method for producing renal interstitial cell
EP4048235A1 (en) 2019-10-23 2022-08-31 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
US20230113077A1 (en) 2020-01-31 2023-04-13 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
WO2024194449A1 (en) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising a diphenylpyrazine derivative

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759297A1 (en) 1995-02-27 1997-02-26 Toray Industries, Inc. Remedy for pulmonary heart
WO2002088084A1 (fr) 2001-04-26 2002-11-07 Nippon Shinyaku Co., Ltd. Derives de composes heterocycliques et medicaments
EP1380307A1 (en) 2001-04-18 2004-01-14 Fujisawa Pharmaceutical Co., Ltd. Tissue fibrosis inhibitors
WO2006113704A2 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
WO2010018549A2 (en) 2008-08-13 2010-02-18 Actelion Pharmaceuticals Ltd Therapeutic compositions containing macitentan
WO2010075861A2 (en) 2008-12-30 2010-07-08 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
US8629145B2 (en) * 2008-06-23 2014-01-14 Nippon Shinyaku Co., Ltd. Therapeutic agent for spinal canal stenosis
US8889693B2 (en) * 2008-02-28 2014-11-18 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
US9284280B2 (en) * 2009-06-26 2016-03-15 Nippon Shinyaku Co., Ltd. Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046233A (en) 1995-02-27 2000-04-04 Toray Industries, Inc. Agent for treating cor pulmonale
EP0759297A1 (en) 1995-02-27 1997-02-26 Toray Industries, Inc. Remedy for pulmonary heart
EP1380307A1 (en) 2001-04-18 2004-01-14 Fujisawa Pharmaceutical Co., Ltd. Tissue fibrosis inhibitors
US20040116530A1 (en) * 2001-04-18 2004-06-17 Noriaki Maeda Tissue fibrosis inhibitors
US7205302B2 (en) * 2001-04-26 2007-04-17 Nippon Shinyaku Co., Ltd. Heterocyclic compound derivatives and medicines
WO2002088084A1 (fr) 2001-04-26 2002-11-07 Nippon Shinyaku Co., Ltd. Derives de composes heterocycliques et medicaments
US20040102436A1 (en) 2001-04-26 2004-05-27 Tetsuo Asaki Heterocyclic compound derivatives and medicines
WO2006113704A2 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
US8889693B2 (en) * 2008-02-28 2014-11-18 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
US8629145B2 (en) * 2008-06-23 2014-01-14 Nippon Shinyaku Co., Ltd. Therapeutic agent for spinal canal stenosis
WO2010018549A2 (en) 2008-08-13 2010-02-18 Actelion Pharmaceuticals Ltd Therapeutic compositions containing macitentan
WO2010075861A2 (en) 2008-12-30 2010-07-08 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
US9284280B2 (en) * 2009-06-26 2016-03-15 Nippon Shinyaku Co., Ltd. Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
US9340516B2 (en) * 2009-06-26 2016-05-17 Nippon Shinyaku Company, Ltd. Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl) acetamide, method for producing the same, and use thereof
US9440931B2 (en) * 2009-06-26 2016-09-13 Nippon Shinyaku Co., Ltd. Form-III crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and use thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A. Nakamura et al., "Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist", Bioorganic & Medicinal Chemistry, vol. 15, 2007, pp. 7720-7725.
Extended European Search Report, dated Nov. 23, 2011, which issued during prosecution of European Application No. 09714302.8, which corresponds to U.S. Pat. No. 8,729,086 B2.
Kuwano, K., et al. "2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butox]-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug", Journal of Pharmacology and Experimental Therapeutics (2007), vol. 322, No. 3, pp. 1181-1188.
Liu, X., et al. "Fibrotic lung fibroblasts show blunted inhibition by cAMP due to deficient CREB phosphorylation", American Society for Pharmacology and Experimental Therapeutics, Aug. 3, 2005, JPET #90324.
PCT International Preliminary Report on Patentability for PCT/JP2009/053582 issued on Oct. 12, 2010.
Shinsuke Murakami et al., "Investigation of therapeutic effect on pulmonary fibrosis of a long-acting PGI2 agonist (ONO-1301) which simultaneously has an inhibitory effect on TXA2 synthetase", Abstract No. 98, The Journal of the Japanese Respiratory Society, 2005, vol. 43, pp. 253.
Shinsuke Murakami et al., "Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice", Am. J. Physiol. Lung Cell Mol. Physiol., 290, pp. L59-L65, 2006. First published Sep. 9, 2005.

Also Published As

Publication number Publication date
US20140221397A1 (en) 2014-08-07
SI2246336T1 (sl) 2020-09-30
EP2246336A4 (en) 2011-12-21
EP2246336B1 (en) 2020-07-01
JPWO2009107736A1 (ja) 2011-07-07
RU2010139644A (ru) 2012-04-10
CY1123308T1 (el) 2021-12-31
ES2817557T3 (es) 2021-04-07
CN104761509A (zh) 2015-07-08
BRPI0908491A2 (pt) 2015-08-11
US8729086B2 (en) 2014-05-20
US8889693B2 (en) 2014-11-18
CA2716554C (en) 2017-01-10
AU2009218115B2 (en) 2013-05-30
HUE050786T2 (hu) 2021-01-28
DK2246336T3 (da) 2020-07-20
HRP20201352T1 (hr) 2020-11-27
US20110015211A1 (en) 2011-01-20
WO2009107736A1 (ja) 2009-09-03
CA2716554A1 (en) 2009-09-03
EP2246336A1 (en) 2010-11-03
KR20100135726A (ko) 2010-12-27
KR101581059B1 (ko) 2015-12-30
RU2497525C2 (ru) 2013-11-10
LT2246336T (lt) 2020-08-25
PL2246336T3 (pl) 2020-12-14
CN101959868A (zh) 2011-01-26
MX2010008745A (es) 2010-08-30
JP5522030B2 (ja) 2014-06-18
AU2009218115A1 (en) 2009-09-03
PT2246336T (pt) 2020-07-29

Similar Documents

Publication Publication Date Title
USRE46364E1 (en) Fibrosis inhibitor
CA2728161C (en) Therapeutic agent for inflammatory bowel disease
US8629145B2 (en) Therapeutic agent for spinal canal stenosis
KR101599082B1 (ko) 피라진 유도체 및 단백질 키나아제 억제제로서의 이의 용도
US9376429B2 (en) Sodium channel blockers, preparation method thereof and use thereof
JP2003522163A (ja) Ｅｒｋのインヒビターとして有用なピラゾール組成物
CN101505747A (zh) 作为细胞增殖抑制剂的吡嗪酮
CN101959879A (zh) 用于治疗和预防1型和2型糖尿病的5-氧代-2,3,4,5-四氢-苯并[b]氧杂䓬-4-甲酸酰胺和2,3-二氢-苯并[b]氧杂䓬-4-甲酸酰胺
JP7021405B2 (ja) イソクエン酸脱水素酵素（ｉｄｈ）阻害剤
KR20130141514A (ko) 치환된 피리다진 카복사미드 화합물
EP3620457A1 (en) Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating tyro 3 related disease comprising same as active ingredient
ES2401578T3 (es) Piridinilacetonitrilos
US7960425B2 (en) Pyrazole compounds and thrombopoietin receptor activators
JP2012092079A (ja) 育毛剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: NIPPON SHINYAKU CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MURAKAMI, KOJI;TORAMOTO, TAKUYA;REEL/FRAME:038600/0986

Effective date: 20100811

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8